The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum Meeting Abstract


Authors: Monk, B. J.; Grisham, R. N.; Marth, C.; Banerjee, S. N.; Hilpert, F.; Coleman, R. L.; Pujade-Lauraine, E.; Pignata, S.; Mirza, M. R.; Oza, A. M.; Del Campo, J. M.; Oehler, M. K.; James, A.; Christy-Bittel, J.; Barrett, E.; Boyd, A. P.; Vergote, I.
Abstract Title: The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
Meeting Title: 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036904799
PROVIDER: wos
Notes: Meeting Abstract: TPS5610 -- Source: Wos